fatigue from tirzepatide Understanding and Management Tirzepatide Week 2: Not What

Practitioners hesitancy to start new medications due to perceived titration complexity, incomplete understanding of drug interactions, and uncertainty of monitoring tools and goals of care, coupled with a belief that GLP-1R agonists requiring subcutaneous injections would not be well received by patients are major barriers to optimal use

GLP-1 receptor agonists, including medications such as semaglutide (Wegovy) and tirzepatide (Zepbound), are FDA-approved for specific medical conditions and are increasingly accessible through telehealth platforms

We focus on small-batch production, transparent testing, and clear documentation so researchers know exactly what theyre working with

Hoenigl et al., 2021

Reported in the early weeks of treatment